Amgen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bearish -45

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

AI-generated analysis

📉 Amgen stock dropped 10% to $394.38, interrupting a 23% year-to-date gain, as markets punished the company for its exposure to the Lp(a) drug class following Novartis's trial failure.

🧬 Amgen announced positive Phase 3 results for IMDELLTRA in small cell lung cancer on the same day, showing statistically significant improvement in overall survival with AstraZeneca's Imfinzi.

⚠️ The company's Olpasiran asset is identified as the most exposed pipeline item to the class-wide re-rating caused by Novartis's pelacarsen miss in the cardiovascular outcomes trial.

💰 Repatha continues to drive growth, generating $876 million in Q1 2026 revenue with 34% year-over-year growth and 35% volume expansion.

📅 Investors are watching for Amgen's presentation at the 2026 Wells Fargo Healthcare Conference as the next major catalyst to clarify the Lp(a) hypothesis viability.

🏛️ As a major holding in the Health Care Select Sector SPDR ETF (XLV), Amgen's decline contributed to sector pressure despite Novartis not being a direct component of the fund.

Bullish Signals
  • Amgen successfully met its primary endpoint in the Phase 3 DeLLphi-305 study for IMDELLTRA, demonstrating statistically significant improvement in overall survival for extensive stage small cell lung cancer.
  • Repatha remains a high-growth driver within the cholesterol franchise, delivering $876 million in Q1 2026 revenue with 34% year-over-year growth and 35% volume growth.
Risk Factors
  • Amgen shares fell 10% as the market repriced Lp(a) pipeline risk sectorwide following Novartis's failed pelacarsen trial, directly impacting Amgen's Olpasiran asset.
  • The failure of Novartis's pelacarsen study has weakened the Lp(a) hypothesis, forcing investors to reweight the odds on Amgen's remaining cardiovascular programs despite its own positive oncology data.
Full Analysis
Amgen (AMGN) shares fell 10% to $394.38 in Tuesday trading, driven by a sector-wide repricing of Lp(a) cholesterol drugs following Novartis's failed pelacarsen trial. Despite Amgen posting positive Phase 3 results for its IMDELLTRA study in small cell lung cancer on the same morning, investors penalized the company heavily due to its exposure to the broader Lp(a) hypothesis. The market reaction highlights a specific risk to Amgen's pipeline: its Olpasiran asset, an Lp(a)-lowering therapy currently in Phase 3 OCEAN(a)-Outcomes trials, is now viewed as highly exposed to the class-wide skepticism triggered by Novartis. Analysts suggest that while the mechanism of lowering Lp(a) might be flawed or the trial design at issue, the immediate consequence is a re-rating of all remaining programs in this space. Amgen's cholesterol franchise remains robust, with Repatha generating $876 million in Q1 2026 revenue and growing 34% year-over-year. However, the stock's decline underscores the market's tendency to treat pipeline assets as correlated bets, even when distinct molecules like Amgen's Olpasiran and Eli Lilly's VERVE-102 utilize different technical approaches. Looking ahead, investors are advised to monitor follow-up commentary from cardiology leaders and await Amgen's presentation at the 2026 Wells Fargo Healthcare Conference. This upcoming event is expected to be a key catalyst for reframing the narrative around the Lp(a) class and determining whether the recent selloff reflects a failed drug or a fundamental failure of the underlying hypothesis.